Characteristics of subjects in the primary cell study
| Subjects (n) | Non-COPD | COPD | p Value | ||
| 17 | 13 | ||||
| Age (years) | 67.0 | (62.5–75.0) | 68.0 | (65.5–73.5) | 0.642 |
| M/F | 8/9 | 12/1 | 0.017 | ||
| Ex-smokers/never-smokers | 6/11 | 13/0 | <0.001 | ||
| Smoking history (pack-year) | 0.5 | (0.0–29.6) | 55 | (37.0–69.0) | <0.001 |
| FVC (L) | 3.05 | (2.52–3.73) | 3.47 | (3.11–3.71) | 0.110 |
| FVC %predicted | 110.5 | (93.4–118.4) | 99.1 | (92.8–112.9) | 0.379 |
| FEV1 (L) | 2.34 | (2.01–2.79) | 2.27 | (1.85–2.48) | 0.425 |
| FEV1 %predicted | 103.7 | (94.9–114.9) | 79.4 | (69.2–92.3) | <0.001 |
| FEV1/FVC (%) | 80.4 | (76.2–84.3) | 67.2 | (56.2–68.4) | <0.001 |
| DLCO %predicted | 116.1 | (91.1–138.1) | 90.4 | (72.0–105.3) | 0.009 |
| DLCO/VA %predicted | 98.5 | (90.2–110.6) | 83.7 | (61.1–95.3) | 0.005 |
| GOLD stage (I/II/III/IV) | – | 6/5/2/0 | |||
| Treatment (LAMA alone/LABA alone) (n) | – | 7/2 | |||
Data are presented as the median (with interquartile ranges). Data were analysed using a Wilcoxon rank sum test or Fisher’s exact test.
DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease; LABA, long-acting β2 antagonist; LAMA, long-acting muscarinic antagonist; VA, alveolar volume.